Sagimet Advances MASH and Acne Pipeline with Key Clinical and Regulatory Milestones
Event summary
- Completed Phase 1 PK clinical trial of denifanstat and resmetirom combination, showing no safety signals.
- Plans to initiate Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients in 2H 2026.
- Secured global, exclusive license to TAPI’s innovative forms of resmetirom API for potential fixed-dose combination.
- First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing for acne indication.
- China’s NMPA accepted Ascletis’ NDA for denifanstat in moderate to severe acne.
The big picture
Sagimet’s progress in both MASH and acne programs highlights its strategic focus on targeting metabolic and fibrotic pathways. The company’s ability to secure key partnerships and regulatory acceptance positions it to potentially fill critical gaps in treatment options for severe liver disease and acne. The broader industry trend of developing combination therapies for complex diseases underscores the significance of Sagimet’s pipeline advancements.
What we're watching
- Clinical Progress
- Whether the Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients will demonstrate efficacy and advance the treatment landscape for this high-risk population.
- Regulatory Pathway
- The pace at which Ascletis can secure NMPA approval for denifanstat in acne and potentially expand its use in other indications.
- Financial Sustainability
- How Sagimet will manage its cash runway of $113.1 million amid ongoing clinical trials and potential future development costs.